Meszaros Katharina, Liniger Sophia, Czerny Martin, Stanger Olaf, Reineke David, Englberger Lars, Carrel Thierry P
Department for Cardiovascular Surgery, University Hospital Berne, Berne, Switzerland Department for General Surgery, Medical University of Graz, Graz, Austria.
Department for Cardiovascular Surgery, University Hospital Berne, Berne, Switzerland.
Interact Cardiovasc Thorac Surg. 2014 Oct;19(4):584-9. doi: 10.1093/icvts/ivu186. Epub 2014 Jul 3.
To report the mid-term results of aortic root replacement using a self-assembled biological composite graft, consisting of a vascular tube graft and a stented tissue valve.
Between January 2005 and December 2011, 201 consecutive patients [median age 66 (interquartile range, IQR, 55-77) years, 31 female patients (15.4%), median logistic EuroSCORE 10 (IQR 6.8-23.2)] underwent aortic root replacement using a stented tissue valve for the following indications: annulo-aortic ectasia or ascending aortic aneurysm with aortic valve disease in 162 (76.8%) patients, active infective endocarditis in 18 (9.0%) and acute aortic dissection Stanford type A in 21 (10.4%). All patients underwent clinical and echocardiographic follow-up. We analysed survival and valve-related events.
The overall in-hospital mortality rate was 4.5%. One- and 5-year cardiac-related mortality rates were 3 and 6%, and overall survival was 95 ± 1.5 and 75 ± 3.6%, respectively. The rate of freedom from structural valve failure was 99% and 97 ± 0.4% at the 1- and 5-year follow-up, respectively. The incidence rates of prosthetic valve endocarditis were 3 and 4%, respectively. During a median follow-up of 28 (IQR 14-51) months, only 2 (1%) patients required valve-related redo surgery due to prosthetic valvular endocarditis and none suffered from thromboembolic events. One percent of patients showed structural valve deterioration without any clinical symptoms; none of the patients suffered greater than mild aortic regurgitation.
Aortic root replacement using a self-assembled biological composite graft is an interesting option. Haemodynamic results are excellent, with freedom from structured valve failure. Need for reoperation is extremely low, but long-term results are necessary to prove the durability of this concept.
报告使用由血管管状移植物和带支架组织瓣膜组成的自组装生物复合移植物进行主动脉根部置换的中期结果。
2005年1月至2011年12月期间,201例连续患者[年龄中位数66岁(四分位间距,IQR,55 - 77岁),女性患者31例(15.4%),逻辑EuroSCORE中位数10(IQR 6.8 - 23.2)]因以下指征接受了带支架组织瓣膜的主动脉根部置换:162例(76.8%)患者为瓣环-主动脉扩张或升主动脉瘤合并主动脉瓣疾病,18例(9.0%)为活动性感染性心内膜炎,21例(10.4%)为急性A型主动脉夹层。所有患者均接受了临床和超声心动图随访。我们分析了生存率和瓣膜相关事件。
总体住院死亡率为4.5%。1年和5年心脏相关死亡率分别为3%和6%,总体生存率分别为95±1.5%和75±3.6%。1年和5年随访时无结构性瓣膜功能障碍的发生率分别为99%和97±0.4%。人工瓣膜心内膜炎的发生率分别为3%和4%。在中位随访28(IQR 14 - 51)个月期间,仅2例(1%)患者因人工瓣膜心内膜炎需要进行瓣膜相关再次手术,且无患者发生血栓栓塞事件。1%的患者出现结构性瓣膜退化但无任何临床症状;无患者出现大于轻度的主动脉瓣反流。
使用自组装生物复合移植物进行主动脉根部置换是一个有吸引力的选择。血流动力学结果极佳,无结构性瓣膜功能障碍。再次手术的需求极低,但需要长期结果来证明这一概念的耐久性。